Sanofi: First-quarter 2018 Business EPS(1) up 1.4% at CER

NEXT STORY
FIT Biotech Oy: APPOINTMENT OF TOMMI HOLOPAINEN AS CFO AND AS A MEMBER OF THE MANAGEMENT TEAM OF FIT BIOTECH
PREV STORY
ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cerner Announces Strategic Alignment With Glens Falls Hospital to Consolidate Its EHR Platform

KANSAS CITY, Mo., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Glens Falls Hospital, a comprehensive ...

author_avatar
NASDAQ Market News

Athersys Announces Enrollment of First Patient in Masters-2 Phase 3 Study of Multistem® Treatment for Ischemic Stroke

Pivotal study has received a Special Protocol Assessment (SPA), Fast Track Designation, and Regenerative ...

author_avatar
NASDAQ Market News

Celsion to Host Research and Development Update October 12, 2017

LAWRENCEVILLE, N.J., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology development ...

author_avatar
NASDAQ Market News